Wallander Karin M, Ohman Inger, Dahlin Maria
Department of Neuropediatrics, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.
Department of Internal Medicine, Center for Pharmacoepidemiology, Karolinska Institute, Stockholm, Sweden.
Neuropediatrics. 2014 Dec;45(6):362-70. doi: 10.1055/s-0034-1387815. Epub 2014 Aug 18.
Zonisamide is a new generation antiepileptic drug (AED) widely used in children with refractory epilepsy, although until recently, it was used to a large extent as off-label or unlicensed medication due to the lack of evidence-based studies. Children have a different pharmacokinetic profile than adults and an adult dose regimen cannot be directly translated into pediatric use. Patients and
In this retrospective noninterventional study of the medical records of 75 children with pharmacoresistant epilepsy, the pharmacokinetics, efficacy and safety of zonisamide were examined. The dose-to-concentration ratio, the daily weight-normalized dose of zonisamide divided by its plasma concentration, was used as a measure of clearance. In addition, data on the efficacy of zonisamide to reduce seizures and reported adverse events were extracted from the medical records and analyzed.
Young children (range, 0-4 years) had a significantly increased zonisamide clearance compared with older ones (range, 5-17 years) and those with enzyme-inducing comedication (carbamazepine, phenobarbital, or phenytoin) had increased clearance compared with those on nonenzyme inducers; the increases were 1.7-fold and 1.8-fold, respectively. No significant difference in clearance was found between female and male subjects. The clearances of concomitant AEDs were not affected by zonisamide administration. The overall efficacy of zonisamide for reducing seizure frequency ≥ 50% was 35% and the most frequent adverse event was fatigue, reported in 23% of the patients.
Patients with enzyme-inducing comedication or of young age (range, 0-4 years) might need higher weight-normalized doses to achieve the same plasma levels as in patients with no enzyme-inducing comedication or patients of older age. Zonisamide was not found to influence the pharmacokinetics of concomitant AEDs. The shortage of pharmacokinetic studies of zonisamide in children highlights the need for research of this kind.
唑尼沙胺是一种新一代抗癫痫药物(AED),广泛用于治疗难治性癫痫患儿,尽管直到最近,由于缺乏循证研究,它在很大程度上仍被用作标签外或未获许可的药物。儿童的药代动力学特征与成人不同,成人剂量方案不能直接用于儿科。
在这项对75例药物难治性癫痫患儿病历的回顾性非干预性研究中,检测了唑尼沙胺的药代动力学、疗效和安全性。剂量-浓度比,即唑尼沙胺每日体重标准化剂量除以其血浆浓度,用作清除率的指标。此外,从病历中提取并分析了唑尼沙胺减少癫痫发作的疗效数据以及报告的不良事件。
幼儿(年龄范围0 - 4岁)与年龄较大者(年龄范围5 - 17岁)相比,唑尼沙胺清除率显著增加,服用酶诱导联合用药(卡马西平、苯巴比妥或苯妥英)者与未服用酶诱导剂者相比清除率增加;增加倍数分别为1.7倍和1.8倍。男性和女性受试者之间的清除率未发现显著差异。联合使用的抗癫痫药物的清除率不受唑尼沙胺给药的影响。唑尼沙胺使癫痫发作频率降低≥50%的总体疗效为35%,最常见的不良事件是疲劳,23%的患者报告有此症状。
服用酶诱导联合用药的患者或幼儿(年龄范围0 - 4岁)可能需要更高的体重标准化剂量才能达到与未服用酶诱导联合用药的患者或年龄较大患者相同的血浆水平。未发现唑尼沙胺会影响联合使用的抗癫痫药物的药代动力学。儿童唑尼沙胺药代动力学研究的不足凸显了此类研究的必要性。